Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2025-08-26 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2025年度向特定对象发行A股股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a company's 2025 issuance of A shares to specific investors. It references multiple regulatory laws and rules, including the Securities Law, Company Law, and Securities Issuance Registration Measures. It includes detailed legal analysis of the issuance's approval, authorization, the issuer's qualifications, business scope, shareholders, and compliance with relevant laws. The document also references various audit reports and financial statements but does not itself contain financial statements or earnings data. It is a legal opinion related to a capital raising event (a non-public issuance of shares). This type of document is best classified as a Capital/Financing Update (CAP) because it provides legal opinions and confirmations related to a capital issuance and financing activity. It is not an annual report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report. The length and content confirm it is a substantive legal opinion on financing.
2025-08-26 Chinese
北京神州细胞生物技术集团股份公司2025年度向特定对象发行A股股票募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a specific stock issuance. It details the company's plan for a 2025 targeted issuance of A shares, including the issuance scheme, pricing, number of shares, use of proceeds, risk factors, and commitments by management and controlling shareholders. It references regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document is comprehensive and includes financial impact analysis, risk disclosures, and governance commitments related to the capital raising. This type of document is a detailed capital raising disclosure, not a general annual report, earnings release, or management discussion. It is specifically about a financing event involving issuance of new shares to specific investors. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the full disclosure, not just an announcement or a brief summary.
2025-08-26 Chinese
神州细胞关于2025年度向特定对象发行A股股票申请获得上海证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the acceptance by the Shanghai Stock Exchange of their application for a specific issuance of A-shares. It mentions the receipt of a notice from the exchange about the acceptance of the securities issuance application and states that the issuance is subject to further approval by the China Securities Regulatory Commission. The document is short (597 characters) and serves as an announcement of the acceptance and ongoing review process rather than the issuance itself or detailed financial data. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-08-26 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2025年度向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to a 2025 specific share issuance by Beijing Sinocelltech Group Limited. It contains detailed information about the securities issuance, including the sponsor's commitments, the issuer's financial data, shareholder structure, legal compliance, and regulatory adherence. The document is a formal application and recommendation for a specific share issuance to a particular investor, including due diligence and regulatory compliance statements. It is not a general annual or quarterly report, nor an earnings release or call transcript. It is not a proxy statement or voting result announcement. It is a detailed sponsorship letter related to a capital raising event (specific share issuance). Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive financial and procedural details about the issuance, not just an announcement or a brief summary, so it is not an RPA or RNS. Confidence is high due to the clear focus on a specific share issuance and sponsorship.
2025-08-26 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2025年度向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to the 2025 issuance of A shares by Beijing Sinocelltech Group Limited. It contains detailed information about the issuer, the issuance plan, pricing, number of shares, use of proceeds, and risk factors. The document is a formal application and sponsorship letter for a specific share issuance to particular investors, including financial data and issuance details. This type of document is related to capital raising and financing activities rather than a general annual report or earnings release. It is not a simple announcement or a report publication notice but a comprehensive filing related to a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content support a high confidence in this classification.
2025-08-26 Chinese
信永中和会计师事务所（特殊普通合伙）关于北京神州细胞生物技术集团股份公司向特定对象发行股票的财务报告及审计报告
Audit Report / Information Classification · 95% confidence The document is titled “审计报告” and contains the auditor’s opinion, basis for opinion, key audit matters, auditor and management responsibilities, followed by the consolidated balance sheet and other financial statements. It is a standalone audit report (with financial statements) rather than a full annual report or an announcement of a report. Therefore, it fits the Audit Report / Information category. FY 2024
2025-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.